EP3972637A4 - Compositions and methods of manufacturing trivalent filovirus vaccines - Google Patents

Compositions and methods of manufacturing trivalent filovirus vaccines Download PDF

Info

Publication number
EP3972637A4
EP3972637A4 EP20810813.4A EP20810813A EP3972637A4 EP 3972637 A4 EP3972637 A4 EP 3972637A4 EP 20810813 A EP20810813 A EP 20810813A EP 3972637 A4 EP3972637 A4 EP 3972637A4
Authority
EP
European Patent Office
Prior art keywords
trivalent
compositions
manufacturing
methods
filovirus vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20810813.4A
Other languages
German (de)
French (fr)
Other versions
EP3972637A1 (en
Inventor
Oreola Donini
Axel LEHRER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Hawaii
Soligenix Inc
Original Assignee
University of Hawaii
Soligenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Hawaii, Soligenix Inc filed Critical University of Hawaii
Publication of EP3972637A1 publication Critical patent/EP3972637A1/en
Publication of EP3972637A4 publication Critical patent/EP3972637A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
    • C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/14011—Filoviridae
    • C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
    • C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
EP20810813.4A 2019-05-20 2020-05-20 Compositions and methods of manufacturing trivalent filovirus vaccines Pending EP3972637A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962850443P 2019-05-20 2019-05-20
PCT/US2020/033864 WO2020236973A1 (en) 2019-05-20 2020-05-20 Compositions and methods of manufacturing trivalent filovirus vaccines

Publications (2)

Publication Number Publication Date
EP3972637A1 EP3972637A1 (en) 2022-03-30
EP3972637A4 true EP3972637A4 (en) 2023-06-21

Family

ID=73458117

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20810813.4A Pending EP3972637A4 (en) 2019-05-20 2020-05-20 Compositions and methods of manufacturing trivalent filovirus vaccines

Country Status (10)

Country Link
US (2) US11433129B2 (en)
EP (1) EP3972637A4 (en)
CN (1) CN114302737A (en)
AU (1) AU2020277403A1 (en)
CA (1) CA3141460A1 (en)
GB (2) GB2619625B (en)
IL (1) IL288240A (en)
SG (1) SG11202112887TA (en)
WO (1) WO2020236973A1 (en)
ZA (1) ZA202110437B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3141460A1 (en) * 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120136142A1 (en) * 2008-09-03 2012-05-31 Southern Research Institute Vaccine Compositions For Marburg Virus
WO2019051098A1 (en) * 2017-09-07 2019-03-14 Hawaii Biotech Inc. Filovirus vaccine and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0835663T3 (en) 1992-05-23 2010-02-01 Glaxosmithkline Biolog Sa Combined vaccines comprising Hepatitis B surface antigen and other antigens
ES2325301T3 (en) 1995-06-23 2009-09-01 Glaxosmithkline Biologicals S.A. VACCINE COMPOSITION THAT INCLUDES A CONJUGATED POLISACARIDE ANTIGEN, ADSORBED ON ALUMINUM PHOSPHATE.
SK283565B6 (en) 1996-07-02 2003-09-11 Connaught Laboratories Limited Multivalent DTP-polio vaccines
DK1028750T3 (en) 1997-09-15 2006-05-22 Sanofi Pasteur Msd Process for the preparation of multivalent vaccines
RU2130778C1 (en) 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Mixed vaccine for immune prophylaxis of viral hepatitis b, tetanus, diphtheria and whooping cough
PE20020126A1 (en) 2000-06-29 2002-04-27 Smithkline Beecham Biolog VACCINE COMPOSITION
HUP0500539A2 (en) * 2002-02-04 2006-09-28 Corixa Corp New immunoeffector 2-deoxi-2-amino-3-d glucopyranose derivatives
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7947286B2 (en) * 2005-10-07 2011-05-24 Panthera Biopharma Llc Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
US8753646B2 (en) 2006-09-29 2014-06-17 Japan Poliomyelitis Research Institute IPV-DPT vaccine
AU2008231072B2 (en) 2007-03-22 2013-08-01 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
CA2725381A1 (en) * 2008-05-23 2010-03-25 The Regents Of The University Of Michigan Nanoemulsion adjuvants
CA2836273C (en) 2011-05-17 2019-01-15 Soligenix, Inc. Thermostable vaccine compositions and methods of preparing same
US10293041B2 (en) * 2014-07-09 2019-05-21 Soligenix, Inc. Multivalent stable vaccine composition and methods of making same
US10449243B2 (en) * 2014-12-22 2019-10-22 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
US10566193B2 (en) * 2015-08-07 2020-02-18 North Carolina State University Synthesis and processing of Q-carbon, graphene, and diamond
KR102632419B1 (en) * 2016-12-23 2024-01-31 인터벳 인터내셔널 비.브이. Combination vaccine for pigs
CA3141460A1 (en) * 2019-05-20 2020-11-26 Soligenix, Inc. Compositions and methods of manufacturing trivalent filovirus vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120136142A1 (en) * 2008-09-03 2012-05-31 Southern Research Institute Vaccine Compositions For Marburg Virus
WO2019051098A1 (en) * 2017-09-07 2019-03-14 Hawaii Biotech Inc. Filovirus vaccine and methods of use

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GROSS LISE ET AL: "Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination", INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, INTERNATIONAL SOCIETY FOR INFECTIOUS DISEASES, HAMILTON, CA, vol. 74, 5 July 2018 (2018-07-05), pages 83 - 96, XP085462068, ISSN: 1201-9712, DOI: 10.1016/J.IJID.2018.06.022 *
LEHRER AXEL T ET AL: "Recombinant proteins of Zaire ebola virus induce potent humoral and cellular immune responses and protect against live virus infection in mice", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 36, no. 22, 16 February 2017 (2017-02-16), pages 3090 - 3100, XP085393884, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2017.01.068 *
LEHRER AXEL: "DEVELOPMENT OF THERMOSTABLE FILOVIRUS VACCINES BASED ON RECOMBINANT INSECT CELL EXPRESSED SUBUNITS", 28 October 2018 (2018-10-28), XP093045383, Retrieved from the Internet <URL:https://www.astmh.org/ASTMH/media/Documents/2018-Abstract-Book-FINAL-11-13.pdf> [retrieved on 20230509] *
ORR MARK T ET AL: "Elimination of the cold-chain dependence of a nanoemulsion adjuvanted vaccine against tuberculosis by lyophilization", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 177, 29 December 2013 (2013-12-29), pages 20 - 26, XP028621636, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2013.12.025 *
PRESTON KENDALL B ET AL: "Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 39, no. 39, 13 August 2021 (2021-08-13), pages 5650 - 5657, XP086777779, ISSN: 0264-410X, [retrieved on 20210813], DOI: 10.1016/J.VACCINE.2021.08.003 *
PRESTON KENDALL: "Lyophilized Filovirus Glycoprotein Vaccines: Peroxides in a Vaccine Formulation with Polysorbate 80-Containing Adjuvant are Associated with Reduced Neutralizing Antibody Titers in Both Mice and Non-Human Primates", JOURNAL OF PHARMACEUTICAL SCIENCES, 21 May 2022 (2022-05-21), XP093044510 *
REYNOLDS PIERCE ET AL: "Ebola and Marburg virus vaccines", VIRUS GENES, KLUWER ACADEMIC PUBLISHERS, BOSTON, US, vol. 53, no. 4, 26 April 2017 (2017-04-26), pages 501 - 515, XP036278063, ISSN: 0920-8569, [retrieved on 20170426], DOI: 10.1007/S11262-017-1455-X *
VIDYASHANKARA IYER: "Feasibility of Freeze-Drying Oil-in-Water Emulsion Adjuvants and Subunit Proteins to Enable Single-Vial Vaccine Drug Products - ScienceDirect", 24 February 2017 (2017-02-24), pages 1 - 3, XP055982788, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/abs/pii/S0022354917301338> [retrieved on 20221117] *

Also Published As

Publication number Publication date
AU2020277403A1 (en) 2022-01-06
SG11202112887TA (en) 2021-12-30
GB2619625B (en) 2024-04-03
GB202312320D0 (en) 2023-09-27
CN114302737A (en) 2022-04-08
GB2599572B (en) 2023-09-20
WO2020236973A1 (en) 2020-11-26
US11771757B2 (en) 2023-10-03
GB2599572A (en) 2022-04-06
US11433129B2 (en) 2022-09-06
CA3141460A1 (en) 2020-11-26
US20200376109A1 (en) 2020-12-03
GB2619625A (en) 2023-12-13
IL288240A (en) 2022-01-01
WO2020236973A8 (en) 2021-02-04
ZA202110437B (en) 2023-10-25
EP3972637A1 (en) 2022-03-30
US20230093418A1 (en) 2023-03-23
WO2020236973A9 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
EP3841090A4 (en) Specially formulated compositions of inhaled nintedanib and nintedanib salts
EP3269719A4 (en) Crystal form of jak inhibitor and preparation method thereof
EP3892625A4 (en) Acylphosphine oxide compound and preparation method therefor
EP4034253A4 (en) Compositions and methods for increasing the efficacy of immunotherapies and vaccines
EP3841213A4 (en) Methods and compositions for the modification of plants
EP3900741A4 (en) Samrna vaccine and preparation method therefor
EP3829307A4 (en) Bismuth-thiol compositions and methods of use
EP3606493A4 (en) Dental cement compositions and methods of use
EP3731833A4 (en) Compositions containing thymohydroquinone and their method of preparation
EP3842426A4 (en) Preparation method of pyrrolo-amino-pyridazinone compound and intermediate thereof
EP3593785A4 (en) Dental composition and preparation method therefor
EP3668957A4 (en) Furan based compositions and methods of making thereof
EP3615492A4 (en) Cementitious compositions and methods of making and using the same
EP4054330A4 (en) A composition and related methods of manufacture and use
EP3972637A4 (en) Compositions and methods of manufacturing trivalent filovirus vaccines
EP3519568A4 (en) Compositions comprising a modified glcnac-1-phosphotransferase and methods of use thereof
EP4022700A4 (en) Materials and methods of manufacture
EP4005561A4 (en) Nano-micelle preparation of icaritin and preparation method therefor and application thereof
EP3672520A4 (en) Light-absorbing compositions and methods of use
EP3504267A4 (en) Oligoesters compositions and methods of making and using same
EP4081233A4 (en) Composition and methods of manufacture
EP3927372A4 (en) Optimized vaccine compositions and methods for making the same
EP3917320A4 (en) Bacterialcidal methods and compositions
EP3894418A4 (en) Preparation of triiodosilanes
EP3866830A4 (en) Vaccine polypeptide compositions and methods

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40072126

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20230523

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/14 20060101ALI20230516BHEP

Ipc: A61K 39/39 20060101ALI20230516BHEP

Ipc: A61K 39/12 20060101ALI20230516BHEP

Ipc: A61K 39/07 20060101ALI20230516BHEP

Ipc: A61K 39/02 20060101ALI20230516BHEP

Ipc: A61K 39/00 20060101AFI20230516BHEP